239 related articles for article (PubMed ID: 21995322)
1. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ; Smith JT; Schuster M; Dragnev KH; Rigas JR
Expert Opin Biol Ther; 2011 Dec; 11(12):1663-8. PubMed ID: 21995322
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies in lung cancer.
Wang Y; Deng G; Liu X; Cho WC
Expert Opin Biol Ther; 2013 Feb; 13(2):209-26. PubMed ID: 23240766
[TBL] [Abstract][Full Text] [Related]
3. [Bevacizumab in thoracic oncology: results and practical aspects].
Dansin É; Cousin S; Lauridant G; Mennecier B
Rev Pneumol Clin; 2013 Jun; 69(3):159-69. PubMed ID: 23597632
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
5. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents.
Gridelli C; Rossi A; Maione P
Oncogene; 2003 Sep; 22(42):6629-38. PubMed ID: 14528288
[TBL] [Abstract][Full Text] [Related]
6. New insights for IL-6 targeted therapy as an adjuvant treatment for non-small-cell lung cancer.
Zarogoulidis P; Yarmus L; Zarogoulidis K
Ther Deliv; 2013 Oct; 4(10):1221-3. PubMed ID: 24116905
[No Abstract] [Full Text] [Related]
7. The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.
Gridelli C; Rossi A; Bareschino MA; Schettino C; Sacco PC; Maione P
Expert Opin Investig Drugs; 2010 May; 19(5):631-9. PubMed ID: 20367288
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab in non-small-cell lung cancer: a review.
Planchard D
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1163-79. PubMed ID: 21916570
[TBL] [Abstract][Full Text] [Related]
9. Controversies around the use of monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Dediu M; Ion O; Ion R; Gal C; Median D; Gongu M
J BUON; 2009 Sep; 14 Suppl 1():S159-64. PubMed ID: 19785059
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab Shows Promise for NSCLC.
Cancer Discov; 2015 Jun; 5(6):572. PubMed ID: 25895920
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Reck M; Gatzemeier U
Respir Med; 2005 Mar; 99(3):298-307. PubMed ID: 15733505
[TBL] [Abstract][Full Text] [Related]
12. The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Joerger M; Finn SP; Cuffe S; Byrne AT; Gray SG
Expert Opin Ther Targets; 2016 Nov; 20(11):1339-1356. PubMed ID: 27353429
[TBL] [Abstract][Full Text] [Related]
13. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer.
Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J
Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187
[TBL] [Abstract][Full Text] [Related]
15. [Anti-VEGF therapy for lung cancer].
Taira T; Yamamoto N
Nihon Rinsho; 2012 Dec; 70(12):2159-64. PubMed ID: 23259390
[TBL] [Abstract][Full Text] [Related]
16. Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention.
El-Nikhely N; Larzabal L; Seeger W; Calvo A; Savai R
Expert Opin Investig Drugs; 2012 Aug; 21(8):1107-22. PubMed ID: 22667993
[TBL] [Abstract][Full Text] [Related]
17. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
19. Development of new first-line therapeutic options for non-small-cell lung cancer.
Crinò L; Foglietta J; Hamzaj A
Lung Cancer; 2006 Dec; 54 Suppl 2():S19-24. PubMed ID: 17056151
[TBL] [Abstract][Full Text] [Related]
20. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
